<DOC>
	<DOCNO>NCT02348424</DOCNO>
	<brief_summary>This open-label Phase I study plasma , genitourinary , rectal , pharyngeal pharmacokinetics single 1000mg oral dose solithromycin . Study Objectives : The primary objective determine pharmacokinetics solithromycin plasma , vaginal , cervical , seminal , rectal , pharyngeal fluid sample single 1000mg oral dose .</brief_summary>
	<brief_title>Genitourinary Pharyngeal Pharmacokinetics Solithromycin</brief_title>
	<detailed_description>This open-label Phase I study plasma , genitourinary , rectal , pharyngeal pharmacokinetics single 1000mg oral dose solithromycin . A total 28 subject ( 14 male , 14 female ) enrol receive single 1000mg dose solithromycin 12 hour overnight fast ( water permit ) . Solithromycin fluoroketolide antibiotic investigation oral parenteral use administer orally . The study duration approximately 18 month . Study Objectives : The primary objective determine pharmacokinetics solithromycin plasma , vaginal , cervical , seminal , rectal , pharyngeal fluid sample single 1000mg oral dose . The secondary objective determine safety tolerability single 1000 mg oral dose solithromycin healthy adult subject .</detailed_description>
	<mesh_term>Gonorrhea</mesh_term>
	<criteria>Healthy male nonpregnant female subject 18 45 year age ( inclusive ) Body Mass Index ( BMI ) 18 35 kg/m2 ( inclusive ) Female sexually active subject must use one follow acceptable birth control method begin 30 day prior dose 7 day postdose : * Abstinence * Surgical sterilization * Hormonal contraceptive insert vagina ( e.g . NuvaRing , intrauterine device ) Male sexually active subject must use one follow acceptable birth control method 7 day prior dose 7 day dose : * Abstinence * Surgical sterilization Male subject must agree donate sperm 30 day solithromycin dose Willingness ability provide write informed consent Willingness ability adhere lifestyle guideline restriction outline protocol Willingness ability participate study visit require protocol , include optional overnight stay return unit Days 1 , 2 , 3 . Evidence history clinically significant disease current infection . oncologic , pulmonary , hepatic , gastrointestinal , cardiovascular , hematologic , metabolic , neurologic , immunologic , nephrologic , endocrine , psychiatric disease History systemic ( oral parenteral ) antibiotic use within two week prior administration study drug Any condition possibly affect drug absorption ( e.g . status post gastrectomy ) History postantibiotic colitis within three month prior screen ECG QTc &gt; 450msec correct Fridericia formula male female , abnormal , clinically significant finding report overreading board certify cardiologist Blood pressure reading &gt; 140 mmHg ( systolic ) &gt; 90 mm/Hg ( diastolic ) Participation another research study receipt investigational agent within 30 day administration study drug * Investigational agent may include vaccine , drug , biologic , device , blood product , medication . Use spermicide , intrauterine device ( IUD ) , diaphragm , and/or vaginally insert hormonal contraceptive ( e.g . NuvaRing ) seven day prior dose Treatment CYP3A4 enzyme alter drug , except hormonal contraceptive topical medication , within 14 day prior treatment study drug : Use systemic prescription drug , vitamin , herbal supplement , opinion investigator may interfere solithromycin metabolism via CYP3A4 , within 14 day prior administration study drug include , limited * Concomitant use drug know prolong QT interval include class 1a ( quinidine , procainamide ) Class III ( amiodarone , sotalol ) , antiarrythmics * Concomitant use drug , food , herbal product know moderate potent inhibitor CYP3A4 isozymes : oral antifungal agent ( e.g . ketoconazole , itraconazole , posaconazole , fluconazole voriconazole ) ; human immunodeficiency virus ( HIV ) protease inhibitor ( e.g . ritonavir saquinavir ) , hepatitis C virus ( HCV ) protease inhibitor ( e.g . boceprevir telaprevir ) , nefazodone , fluvoxamine , conivaptan , diltiazem , verapamil , aprepitant , ticlopidine , crizotinib , imatinib ; grapefruit grapefruit juice . * Any use within prior 7 day drug herbal product know moderate potent inducer CYP3A4 isozymes : St. John 's Wort , rifampin , rifabutin , anticonvulsant ( e.g . phenobarbital , carbamazepine , phenytoin , rufinamide ) , modafinil , armodafinil , etraverine , efavirenz , bosentan . * Required current use drug narrow therapeutic index principally metabolize CYP3A4 transport Pglycoprotein ( Pgp ) , drug interaction solithromycin could result high possibly unsafe exposure drug : e.g . Pgp substrates digoxin colchicine CYP3A4 substrates alfentanil , astemizole , cisapride , cyclosporine , dihydroergotamine , ergotamine , fentanyl , midazolam , pimozide , quinidine , sirolimus , tacrolimus , everolimus , terfenadine . * Use nonprescription medication , vitamin , dietary supplement , unless prior approval grant investigator * Consumption Seville oranges product contain Seville orange component , grapefruit , grapefruit juice within 14 day administration study drug Positive serum pregnancy test breast feeding study Positive test human immunodeficiency virus ( HIV1 ) , hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) antibodies Positive urine drug screen Screening Enrollment ( Day 1 ) ( marijuana , cocaine metabolite , amphetamine , opiate , phencyc lidine , methadone , barbiturate , and/or benzodiazepine ) Positive breathalyzer test alcohol Positive STI screen * GC , CT , syphilis , trichomoniasis , symptomatic bacterial vaginosis ( assessed Amsel criterion ) , vaginal discharge consistent candidiasis ( assessed potassium hydroxide wet preparation ) History clinically significant intolerance hypersensitivity macrolide antibiotic ( determined investigator ) excipients solithromycin capsule . * Clinically significant intolerance define severe nausea vomit standard dose . Note mild nausea common macrolide administration prior history would contraindication . * Likelihood require treatment study drug permit protocol Blood donation significant blood loss ( determined Investigator ) within 56 day screen Plasma donation within seven day screen Laboratory value outside eligibility range protocol ( See protocol page 23 Appendix C ) serum . Laboratory value outside eligibility range protocol ( See protocol page 23 Appendix C ) urinalysis . Uncontrolled intercurrent illness ( i.e . active infection ) fever ( oral temperature &gt; /=100.4 degrees Fahrenheit &gt; /= 38 degree Celsius ) . Known suspected significant underlying illness include limited , clinically significant liver disease , diabetes mellitus , kidney impairment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 5, 2017</verification_date>
	<keyword>genitourinary</keyword>
	<keyword>Neisseriaceae</keyword>
	<keyword>pharyngeal</keyword>
	<keyword>Solithromycin</keyword>
</DOC>